Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine/tipiracil (17.5 mg/m2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg/kg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.

Trial Details

NCT ID
NCT07085169
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Trifluridine/tipiracil (TAS-102) plus bevacizumab
Locations (sample)
  • Sanming, China|26.24861,117.61861
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • age over 60 years old, male and female
  • histologically confirmed adenocarcinoma of the colon or rectum
  • patients with metastatic or advanced unresectable diseases who had received two or more previous chemotherapy regimens or intolerance to last regimen
  • with or without measurable lesions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →